Silu Yang - BeiGene Beijing Co Ltd | 人才画像

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 21 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1%: A Retrospective Analysis of RATIONALE-305

Markus Moehler, Do-Youn Oh,Ken Kato, Tobias Arkenau,Josep Tabernero,Keun-Wook Lee,Sun Young Rha,Hidekazu Hirano,David Spigel,Kensei Yamaguchi,Lucjan Wyrwicz,Umut Disel,Roberto A Pazo-Cid,Lorenzo Fornaro, Yaling Xu, Tao Sheng,Silu Yang, Alysha Kadva,Marcia Cruz-Correa,Rui-Hua Xu

Advances in therapyno. 5 (2025): 2248-2268

Cited0Views0WOSBibtex

Concordance Between the PD-L1 Tumor Area Positivity Score and Combined Positive Score for Gastric or Esophageal Cancers Treated with Tislelizumab

Markus Moehler, Harry H Yoon,Daniel-Christoph Wagner,Silu Yang, Jingwen Shi, Yun Zhang, Han Hu, Christopher La Placa, Yanyan Peng, Wenting Du, Adrienne McCampbell, Wenjie Xu,Zhirong Shen, Hui Xu, Ruiqi Huang,Ken Kato

Modern pathology an official journal of the United States and Canadian Academy of Pathology, Incpp.100793-100793, (2025)

Cited0Views0WOSBibtex

First-Line Tislelizumab Plus Chemotherapy for Advanced Gastric Cancer with Programmed Death-Ligand 1 Expression ≥ 1

Markus Moehler, Do-Youn Oh,Ken Kato, Tobias Arkenau,Josep Tabernero,Keun-Wook Lee,Sun Young Rha,Hidekazu Hirano,David Spigel,Kensei Yamaguchi,Lucjan Wyrwicz,Umut Disel,Roberto A. Pazo-Cid,Lorenzo Fornaro, Yaling Xu, Tao Sheng,Silu Yang, Alysha Kadva,Marcia Cruz-Correa,Rui-Hua Xu

Advances in Therapyno. 5 (2025): 2248-2268

Cited0Views0Bibtex

Rationale 305: Phase 3 Study of Tislelizumab Plus Chemotherapy Vs Placebo Plus Chemotherapy As First-Line Treatment (1L) of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (GC/GEJC)

Markus H. Moehler,Ken Kato,Hendrik-Tobias Arkenau,Do-Youn Oh,Josep Tabernero,Marcia Cruz-Correa,HongWei Wang, Hui Xu, Jiang Li,Silu Yang,Rui-hua Xu

Journal of Clinical Oncologyno. 4_suppl (2023): 286-286

Cited20Views0Bibtex

Co-enrichment of CD8-positive T Cells and Macrophages is Associated with Clinical Benefit of Tislelizumab in Solid Tumors

Dingwei Ye,Jayesh Desai,Jingwen Shi,Si-Yang Maggie Liu,Wei Shen,Tengfei Liu,Yang Shi,Dan Wang, Liang,Silu Yang,Xiaopeng Ma,Wei Jin,Pei Zhang,Ruiqi Huang,Zhirong Shen,Yun Zhang,Yi-Long Wu

BIOMARKER RESEARCH（2023）

Cited7Views0WOSBibtex

A Phase 1/2 Study of the PD-L1 Inhibitor, BGB-A333, Alone and in Combination with the PD-1 Inhibitor, Tislelizumab, in Patients with Advanced Solid Tumours

Jayesh Desai,Peter Fong,Victor Moreno,Sophia Frentzas,Tarek Meniawy,Ben Markman,Mark Voskoboynik, Tahmina Rahman,Nageshwar Budha,John Wu, Jin Marlow,Silu Yang,Emiliano Calvo,Juan Martin-Liberal

BRITISH JOURNAL OF CANCER（2023）

Cited7Views0WOSNATUREBibtex

The Combination of Gene Hyperamplification and PD-L1 Expression As a Biomarker for the Clinical Benefit of Tislelizumab in Gastric/gastroesophageal Junction Adenocarcinoma

Lu Zhihao,Yang Silu,Luo Xuerui,Shi Yang,Lee Jong-Seok,Deva Sanjeev,Liu Tianshu,Chao Yee,Zhang Yun,Huang Ruiqi,Xu Yaling,Shen Zhirong,Shen Lin

Gastric Cancer（2022）

Cited8Views0WOSBibtex

Profiling the Peripheral Blood T Cell Receptor Repertoires of Gastric Cancer Patients

Mengyao Wang,Peng Gao,Laifeng Ren,Jingjing Duan,Silu Yang,Haina Wang,Hongxia Wang,Junning Sun,Xiaoyan Gao, Bo Li,Shuaicheng Li,Wen Su

Frontiers in Immunology（2022）

Cited4Views0WOSBibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn